MA34457B1 - Combinaison d'un composé glyt1 avec des agents antipsychotiques - Google Patents

Combinaison d'un composé glyt1 avec des agents antipsychotiques

Info

Publication number
MA34457B1
MA34457B1 MA35645A MA35645A MA34457B1 MA 34457 B1 MA34457 B1 MA 34457B1 MA 35645 A MA35645 A MA 35645A MA 35645 A MA35645 A MA 35645A MA 34457 B1 MA34457 B1 MA 34457B1
Authority
MA
Morocco
Prior art keywords
combination
glyt1
compound
antipsychotic agents
schizophrenia
Prior art date
Application number
MA35645A
Other languages
English (en)
Inventor
Joseph G Wettstein
Daniela Alberati
Jean-Luc Moreau
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44512856&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34457(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA34457B1 publication Critical patent/MA34457B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une association pharmaceutique combinant un inhibiteur du transporteur de la glycine (GlyT1) et un médicament antipsychotique atypique, ladite association pouvant être utilisée pour traiter les symptômes positifs et négatifs de la schizophrénie.
MA35645A 2010-08-09 2011-08-05 Combinaison d'un composé glyt1 avec des agents antipsychotiques MA34457B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10172316 2010-08-09
PCT/EP2011/063533 WO2012019970A1 (fr) 2010-08-09 2011-08-05 Combinaison d'un composé glyt1 avec des agents antipsychotiques

Publications (1)

Publication Number Publication Date
MA34457B1 true MA34457B1 (fr) 2013-08-01

Family

ID=44512856

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35645A MA34457B1 (fr) 2010-08-09 2011-08-05 Combinaison d'un composé glyt1 avec des agents antipsychotiques

Country Status (28)

Country Link
US (1) US20120035156A1 (fr)
EP (1) EP2603219B1 (fr)
JP (1) JP2013533297A (fr)
KR (1) KR101455947B1 (fr)
CN (1) CN103068388A (fr)
AR (1) AR084401A1 (fr)
AU (1) AU2011288536B2 (fr)
BR (1) BR112013003068A2 (fr)
CA (1) CA2803656A1 (fr)
CL (1) CL2013000378A1 (fr)
CR (1) CR20130027A (fr)
CY (1) CY1115886T1 (fr)
DK (1) DK2603219T3 (fr)
EA (1) EA201291477A1 (fr)
EC (1) ECSP13012431A (fr)
ES (1) ES2521596T3 (fr)
HR (1) HRP20141199T1 (fr)
MA (1) MA34457B1 (fr)
MX (1) MX2013001166A (fr)
NZ (1) NZ604891A (fr)
PE (1) PE20131100A1 (fr)
PL (1) PL2603219T3 (fr)
PT (1) PT2603219E (fr)
SG (1) SG187108A1 (fr)
SI (1) SI2603219T1 (fr)
TW (1) TW201211019A (fr)
WO (1) WO2012019970A1 (fr)
ZA (1) ZA201300434B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4245369A3 (fr) 2011-09-08 2023-11-22 Sage Therapeutics, Inc. Stéroïdes neuroactifs, compositions et leurs utilisations
AU2014243773B2 (en) 2013-03-13 2018-12-13 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
MX2016006742A (es) * 2013-12-03 2016-08-12 Hoffmann La Roche Composicion farmaceutica.
PT3137658T (pt) * 2014-04-30 2022-05-05 Univ Nat Taiwan Uso de compostos conhecidos como inibidores do d-aminoácido oxidase
EP4306114A1 (fr) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxystérols et leurs procédés d'utilisation
WO2016057713A1 (fr) * 2014-10-07 2016-04-14 Sage Therapeutics, Inc. Composés neuroactifs et leurs procédés d'utilisation
SI3319612T1 (sl) 2015-07-06 2021-11-30 Sage Therapeutics, Inc. Oksisteroli in postopki za uporabo le-teh
CA2991311A1 (fr) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols et leurs procedes d'utilisation
MA42410B1 (fr) 2015-07-06 2021-04-30 Sage Therapeutics Inc Oxystérols et leurs méthodes d'utilisation
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA3029900A1 (fr) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols et leurs methodes d'utilisation
JP7149266B2 (ja) 2016-09-30 2022-10-06 セージ セラピューティクス， インコーポレイテッド Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法
CN110267966B (zh) 2016-10-18 2022-07-08 萨奇治疗股份有限公司 氧甾醇及其使用方法
KR102521573B1 (ko) 2016-10-18 2023-04-14 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
MX2020004975A (es) * 2017-11-14 2020-08-24 Sk Biopharmaceuticals Co Ltd Mezcla que contiene compuesto de carbamato para prevencion, mitigacion o tratamiento de esquizofrenia.
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2297458T3 (es) * 2003-08-11 2008-05-01 F. Hoffmann-La Roche Ag Piperazina con grupo fenilo or-sustituido y su empleo como inhibidores de glyti.
WO2006000222A2 (fr) * 2004-06-24 2006-01-05 H. Lundbeck A/S Combinaison d'un antipsychotique et d'un inhibiteur de type 1 transporteur de glycine pour le traitement de la schizophrenie
KR100969402B1 (ko) * 2005-04-08 2010-07-14 화이자 프로덕츠 인크. Ｉ형 글리신 수송 억제제로서의 비시클릭 [3.1.0]헤테로아릴 아미드
GB0612420D0 (en) * 2006-06-22 2006-08-02 Glaxo Group Ltd Compounds
CN101479243B (zh) * 2006-06-28 2013-01-02 安姆根有限公司 甘氨酸转运子-1抑制剂

Also Published As

Publication number Publication date
HRP20141199T1 (hr) 2015-02-13
PE20131100A1 (es) 2013-09-23
US20120035156A1 (en) 2012-02-09
CY1115886T1 (el) 2017-01-25
MX2013001166A (es) 2013-03-22
EA201291477A1 (ru) 2013-06-28
CR20130027A (es) 2013-03-04
CN103068388A (zh) 2013-04-24
EP2603219B1 (fr) 2014-09-17
KR20130045379A (ko) 2013-05-03
AU2011288536A1 (en) 2013-01-31
SG187108A1 (en) 2013-02-28
NZ604891A (en) 2015-01-30
AR084401A1 (es) 2013-05-15
PT2603219E (pt) 2014-11-25
ZA201300434B (en) 2013-09-25
CA2803656A1 (fr) 2012-02-16
CL2013000378A1 (es) 2013-05-03
BR112013003068A2 (pt) 2016-06-28
DK2603219T3 (da) 2014-10-13
WO2012019970A1 (fr) 2012-02-16
KR101455947B1 (ko) 2014-10-28
TW201211019A (en) 2012-03-16
SI2603219T1 (sl) 2014-12-31
EP2603219A1 (fr) 2013-06-19
AU2011288536B2 (en) 2014-10-09
PL2603219T3 (pl) 2015-03-31
ES2521596T3 (es) 2014-11-13
ECSP13012431A (es) 2013-03-28
JP2013533297A (ja) 2013-08-22

Similar Documents

Publication Publication Date Title
MA34457B1 (fr) Combinaison d'un composé glyt1 avec des agents antipsychotiques
MA37740B2 (fr) Seringue
MA32903B1 (fr) Inhibiteurs de proteine-kinases
TNSN08313A1 (fr) Des formes pharmaceutiques resistantes a la modification
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
EA200870409A1 (ru) Антагонисты киназы pi3
CY1111269T1 (el) Ρυθμιστες βενζιμιδαζολης του vr1
CR20120190A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
MA38273A1 (fr) Thérapie de combinaison avec des anticorps anti-her3
MA38096B1 (fr) Solutions mydriatiques et anti-inflammatoires stables sans agents de conservation destinees a etre injectees
EA201270216A1 (ru) Фармацевтический состав
EA201270590A1 (ru) Ингибиторы акт
MA34263B1 (fr) Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)
ES2572001T3 (es) Derivado de bisfurano antivírico como inhibidor de la proteasa del VIH e intermedios del mismo
TR201904327T4 (tr) Dimetilbenzoik asit bileşikleri.
RS53063B (en) MGLU2 AGONISTS
AR122712A2 (es) Composición herbicida
TN2014000060A1 (en) Benzothiazolone compound
MA42166A1 (fr) Seringue
TN2012000301A1 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée
MA34709B1 (fr) Compositions pharmaceutiques
CY1112501T1 (el) Φαρμακευτικες συνθεσεις περιεχουσες λεφλουνομιδη
NI201000139A (es) ASOCIACION DE UN INHIBIDOR DE CORRIENTE SINUSAL If Y DE UN BETA-BLOQUEANTE